We are live on
!
Find out more
XT
XTX Topco Portfolio holdings
AUM
$5.75B
1-Year Est. Return
30.56%
This Fund
S&P 500
This Quarter
Est. Return
+0.17%
1 Year Est. Return
+30.56%
3 Year Est. Return
+70.38%
5 Year Est. Return
+43.83%
10 Year Est. Return
–
AUM
$3.81B
AUM Growth
+$1.88B
(+98%)
Cap. Flow
+$1.94B
Cap. Flow
% of AUM
50.99%
Top 10 Holdings %
Top 10 Hldgs %
5.52%
Holding
3,983
New
1,493
Increased
1,108
Reduced
652
Closed
727
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$25.6M |
| 2 |
JPMorgan Chase
JPM
|
+$21.7M |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$19.7M |
| 4 |
Kroger
KR
|
+$17.9M |
| 5 |
T-Mobile US
TMUS
|
+$15.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$11.3M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$8.42M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$8.34M |
| 4 |
Cisco
CSCO
|
+$8.02M |
| 5 |
Invesco QQQ Trust
QQQ
|
+$8.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 16.84% |
| 2 | Technology | 16.54% |
| 3 | Industrials | 11.45% |
| 4 | Healthcare | 11.32% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3001
Harvard Bioscience
HBIO
$26.7M
| $26.3K | ﹤0.01% |
+3,935
| New | +$23.3K |
|
3002
Beam Global
BEEM
$23.1M
| $26.2K | ﹤0.01% |
17,491
+1,959
| +13% | +$4.5K |
|
|
BVC
3003
BitVentures Limited Ordinary Shares
BVC
$1.79B
| $26.2K | ﹤0.01% |
+22,990
| New | +$25.7K |
|
|
TURB
3004
Turbo Energy
TURB
$16.7M
| $26.1K | ﹤0.01% |
+28,301
| New | +$65.3K |
|
3005
Primech Holdings
PMEC
$16.1M
| $26.1K | ﹤0.01% |
23,906
+9,879
| +70% | +$13.3K |
|
3006
SurgePays
SURG
$6.03M
| $25.9K | ﹤0.01% |
15,519
-674
| -4% | -$1.5K |
|
|
HODO
3007
House of Doge
HODO
$71.9M
| $25.8K | ﹤0.01% |
8,057
+4,034
| +100% | +$33.6K |
|
|
AIFA
3008
All In FutureTech Alliance Inc
AIFA
$11.4M
| $25.8K | ﹤0.01% |
+10,954
| New | +$36K |
|
3009
Marchex
MCHX
$79.3M
| $25.6K | ﹤0.01% |
+15,416
| New | +$26.2K |
|
|
ORGN
3010
DELISTED
Origin Materials
ORGN
| $25.6K | ﹤0.01% |
+4,026
| New | +$58.8K |
|
3011
Curis
CRIS
$9.41M
| $25.5K | ﹤0.01% |
+1,293
| New | +$34.7K |
|
|
GCTS
3012
GCT Semiconductor Holding
GCTS
$171M
| $25.5K | ﹤0.01% |
+21,257
| New | +$29.6K |
|
|
KNDI
3013
Kandi Technologies Group
KNDI
$63.5M
| $25.5K | ﹤0.01% |
32,385
-329
| -1% | -$349 |
|
|
FTRK
3014
Fast Track Group
FTRK
$9.36M
| $25.1K | ﹤0.01% |
32,706
-21,239
| -39% | -$11.7K |
|
3015
BioVie
BIVI
$10M
| $25.1K | ﹤0.01% |
+21,635
| New | +$34.8K |
|
3016
Evogene
EVGN
$5.99M
| $25K | ﹤0.01% |
+22,684
| New | +$26.5K |
|
3017
Sypris Solutions
SYPR
$44.4M
| $24.7K | ﹤0.01% |
+10,133
| New | +$21.9K |
|
3018
Hitek Global
HKIT
$28.1M
| $24.7K | ﹤0.01% |
+3
| New | +$21.9K |
|
|
ORIO
3019
Orion Digital Corp
ORIO
$15.6M
| $24.6K | ﹤0.01% |
+22,993
| New | +$32.7K |
|
3020
NexGel
NXGL
$4.06M
| $24.1K | ﹤0.01% |
14,999
+1,923
| +15% | +$3.97K |
|
3021
Jowell Global
JWEL
$4.42M
| $24K | ﹤0.01% |
+10,430
| New | +$21.2K |
|
3022
ABVC BioPharma
ABVC
$27.6M
| $24K | ﹤0.01% |
11,261
-13,540
| -55% | -$36.3K |
|
|
GAUZ
3023
Gauzy
GAUZ
$5.91M
| $23.9K | ﹤0.01% |
+18,535
| New | +$69.8K |
|
3024
Mustang Bio
MBIO
$4.78M
| $23.6K | ﹤0.01% |
24,073
+5,298
| +28% | +$6.99K |
|
3025
Kiora Pharmaceuticals
KPRX
$11.4M
| $23.6K | ﹤0.01% |
+11,971
| New | +$27.3K |
|
Similar funds
HW
AAM
RWM
SAM
PP
VH
TSW
KIM
XTX Topco's Q4 2025 Portfolio in Review
As of Q4 2025, XTX Topco held 3,983 positions worth $3.81B, up 98% from $1.93B the previous quarter. Its ten largest holdings account for 5.5% of the portfolio.
XTX Topco deployed $1.94B of net new capital in Q4 2025, opening 1,493 new positions and adding to 1,108 existing holdings. Its largest new stake was T-Mobile US: 74,738 shares worth $15.2M.
By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 14% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $8.34M trimmed.
- XTX Topco's largest Q4 2025 buy was T-Mobile US: 74,738 shares worth $15.2M.
- XTX Topco added most to Procter & Gamble in Q4 2025, an estimated $25.6M increase.
- XTX Topco's biggest Q4 2025 reduction was Bristol-Myers Squibb, cutting an estimated $8.34M.
- XTX Topco fully exited Johnson & Johnson in Q4 2025, selling an estimated $11.3M.
- XTX Topco's ten largest holdings make up 5.5% of its $3.81B portfolio in Q4 2025.
- XTX Topco opened 1,493 new positions and closed 727 in Q4 2025.
- XTX Topco's portfolio value rose 98% quarter-over-quarter to $3.81B.
Based on XTX Topco's 13F filing for Q4 2025, filed 17 Feb 2026.